Drugs / Grass MATA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT00104377 | Mar → Nov 2005 | atopic IgE-mediated allergic disorder | Allergy Therapeutics | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02582073 Comparator | Nov 2015 → May 2016 | seasonal allergic rhinitis | Allergy Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-05-21 | Allergy Therapeutics | Results Positive top-line results from Grass Ph II study allergytherapeutics.com ↗
The trial met its primary endpoint of establishing a dose-response relationship and a Phase III dose. |
All press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-07-31 | Allergy Therapeutics | Grass MATA MPL Publications in Allergy Journal allergytherapeutics.com ↗ |
| 2025-02-17 | Allergy Therapeutics | Grass MATA MPL Phase III data published in Allergy allergytherapeutics.com ↗ |
| 2024-11-25 | Allergy Therapeutics | Submission of MAA for Grass MATA MPL allergytherapeutics.com ↗ |
| 2022-12-08 | Allergy Therapeutics | Key updates on Grass MATA MPL and VLP Peanut allergytherapeutics.com ↗ |
| 2020-10-26 | Allergy Therapeutics | Initiation of Grass MATA MPL exploratory study allergytherapeutics.com ↗ |
| 2019-11-26 | Allergy Therapeutics | Update to Grass MATA MPL Ph III clinical programme allergytherapeutics.com ↗ |
| 2018-05-21 | Allergy Therapeutics | Positive top-line results from Grass Ph II study allergytherapeutics.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Grass MATA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02582073 ↗ |
| Known as | Grass MATA MPL | “Grass MATA MPL has been developed to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross reacting grass pollens.” NCT00104377 ↗ |
| Modality | Other / unclassified | “The grass pollen extract is modified with glutaraldehyde to produce the active ingredient, an allergoid.” NCT00104377 ↗ |
| Route | Subcutaneous | “2 subcutaneous injections of different doses of study medication (Grass MATA or placebo) administered 3 weeks apart.” NCT00104377 ↗ |